• Gisèle Pickering, Véronique Morel, and Joelle Micallef.
• Centre de pharmacologie clinique, CHU Clermont-Ferrand, 63003 Clermont-Ferrand, France; Inserm, CIC 1405, Neurodol 1107, 63003 Clermont-Ferrand, France; Laboratoire de pharmacologie, faculté de médecine, Clermont université, 63001 Clermont-Ferrand, France. Electronic address: gisele.pickering@uca.fr.
• Therapie. 2018 Dec 1; 73 (6): 529-539.

AbstractKetamine is frequently used in the management of refractory chronic pain. To date, the level of proof in the literature on ketamine in this type of indication is generally poor and physicians have no consensus or recommendation to support their practice. This narrative review is an update on literature data assessing the efficacy and safety of ketamine in chronic pain. The electronic search of the Medline, PubMed, Google Scholar and Cochrane databases identified a total of 61 articles including randomized and non-randomized trials and 14 international reviews. In view of these data, it is difficult to conclude on the effectiveness of ketamine in this type of indication and on its safety due to the heterogeneity of practice in terms of doses, routes, duration and frequency of administration and especially a lack of clinical trials with a high level of evidence.Copyright © 2018 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

23 keywords...

hide…